XBiotech (XBIT) Stock Price, News & Analysis

Company Overview

XBiotech Inc. is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.

The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients. Data from these studies demonstrated potential benefits in overall survival, symptom control and quality of life measures. XBiotech is also exploring Xilonix® in additional oncology settings as well as in post-surgical inflammation and other conditions driven by IL-1α–mediated pathways.

Beyond its lead candidate, XBiotech is advancing a diversified pipeline of True Human™ antibodies against novel targets in both oncology and inflammatory diseases. The company conducts clinical development programs in North America and Europe, collaborating with research hospitals and cancer centers to evaluate therapeutic potential across multiple indications. Preclinical studies are ongoing to expand the platform into other areas of unmet medical need.

Founded in 2005 by entrepreneur John Simard, XBiotech is headquartered in Austin, Texas, with research operations in Canada and Europe. Laurent Fischer serves as Chief Executive Officer, overseeing corporate strategy, clinical development and manufacturing partnerships. The company’s leadership combines expertise in antibody engineering, clinical oncology and regulatory affairs to advance its pipeline toward potential commercialization.

Key Stats

• Today's Range: $2.38 to $2.48
• 50-Day Range: $2.25 to $2.58
• 52-Week Range: $2.09 to $3.61
• Volume: 23,524 shs
• Average Volume: 36,943 shs
• Market Capitalization: $75.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

XBiotech Stock Analysis - MarketRank™

XBiotech scored higher than 6% of companies evaluated by MarketBeat, and ranked 841st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

XBiotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

XBiotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of XBiotech is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XBiotech is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XBiotech has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.83% of the float of XBiotech has been sold short.

Short Interest Ratio / Days to Cover

XBiotech has a short interest ratio ("days to cover") of 6.63.

Change versus previous month

Short interest in XBiotech has recently increased by 17.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XBiotech does not currently pay a dividend.

Dividend Growth

XBiotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.4 / 5
• News Sentiment: N/A

News Sentiment

XBiotech has a news sentiment score of -1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XBiotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.80% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XBIT
• CIK: 1626878
• Web: www.xbiotech.com
• Phone: (512) 386-2900
• Fax: 512-386-5505
• Employees: 100
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.10%
• Return on Assets: -25.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 39.03
• Quick Ratio: 39.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.43 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 30,490,000
• Free Float: 21,098,000
• Market Cap: $75.62 million
• Optionable: Optionable
• Beta: 0.88